Jones Lang LaSalle Inc vs Oruka Therapeutics Inc. Common Stock — how do they compare? Jones Lang LaSalle Inc trades at $294.36 (market cap $13.58B), while Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.08B). The key difference: Jones Lang LaSalle Inc is far larger — about 2.7× Oruka Therapeutics Inc. Common Stock's market cap, and Oruka Therapeutics Inc. Common Stock is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Jones Lang LaSalle Inc for 71 Days and Oruka Therapeutics Inc. Common Stock for 0 Days on average.
| JLL | ORKA | |
|---|---|---|
Market Cap | $13.58B | $5.08B |
Volume | 414,312 | 685,276 |
Sector | Real Estate | Health |
52-Week High | $392.79 | $113.08 |
52-Week Low | $280.16 | $26.19 |
Typical Hold Time | 71 Days | 0 Days |
Enterprise Value | $16.34B | $4.21B |
Signals from Pluang's Aura AI — not financial advice
JLL trades at $298.32, up 0.07% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 14.16 and P/S of 0.51, alongside consistent earnings beats in recent quarters. Revenue grew to $26.12B in 2025, with net income reaching $792.10M. Recent news highlights acquisitions and positive growth coverage, while analyst consensus is bullish with a $450.50 price target.
The outlook for JLL is positive based on earnings momentum and attractive valuation, though near-term technical weakness and reliance on real estate market cycles present risks. Upside potential exists if the company maintains its earnings beat streak and capitalizes on data center and global real estate growth trends highlighted in recent analyst reports.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →